Life Biosciences has begun human trials for an experimental treatment aimed at reversing glaucoma by regenerating eye nerves. This approach highlights a growing interest in 'reprogramming' as a method to combat age-related diseases. The outcome could have significant implications for vision loss treatments and the broader biotech industry focused on aging. Success may pave the way for more innovative therapies in regenerative medicine.